2025
Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors.
Fa'ak F, Coudray N, Jour G, Ibrahim M, Illa-Bochaca I, Qiu S, Claudio Quiros A, Yuan K, Johnson D, Rimm D, Weber J, Tsirigos A, Osman I. Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors. Clinical Cancer Research 2025 PMID: 40553453, DOI: 10.1158/1078-0432.ccr-24-3720.Peer-Reviewed Original ResearchResponse to ICIImmune checkpoint inhibitorsMetastatic melanoma cohortCheckpoint inhibitorsMelanoma cohortMelanoma treated with immune checkpoint inhibitorsBiomarkers of ICI responseImmune checkpoint inhibitor useImmune checkpoint inhibitor treatmentCohort of melanoma patientsLow tumor stroma ratioProgression-free survivalTumor-stroma ratioSignificant adverse eventsArea under the curvePatient overall survivalMetastatic settingUnresectable melanomaEpithelioid histologyICI responseMelanoma patientsMetastatic melanomaOverall survivalPatient survivalTumor features
2024
Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma
Su D, Djureinovic D, Schoenfeld D, Marquez-Nostra B, Olino K, Jilaveanu L, Kluger H. Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma. JCO Precision Oncology 2024, 8: e2300702. PMID: 38662983, PMCID: PMC11513442, DOI: 10.1200/po.23.00702.Peer-Reviewed Original ResearchConceptsMC1R expressionMelanoma progressionAssociated with shorter survivalStages of melanoma progressionCases of benign neviChronic sun exposureMarkers of progressionHuman melanoma tissuesBreslow thicknessMelanocortin-1Metastatic melanomaOverall survivalPrimary melanomaMetastatic tumorsMelanoma cohortReceptor expressionPredictive biomarkersAggressive melanomaPrimary lesionTissue microarrayShorter survivalMale sexQuantitative immunofluorescenceBenign neviClinical trials
2020
Detection of Pathogenic Variants With Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients With Prostate Cancer and Melanoma
AlDubayan S, Conway J, Camp S, Witkowski L, Kofman E, Reardon B, Han S, Moore N, Elmarakeby H, Salari K, Choudhry H, Al-Rubaish A, Al-Sulaiman A, Al-Ali A, Taylor-Weiner A, Van Allen E. Detection of Pathogenic Variants With Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients With Prostate Cancer and Melanoma. JAMA 2020, 324: 1957-1969. PMID: 33201204, PMCID: PMC7672519, DOI: 10.1001/jama.2020.20457.Peer-Reviewed Original ResearchMeSH KeywordsCross-Sectional StudiesDeep LearningDNA Mutational AnalysisFemaleGenetic Predisposition to DiseaseGenetic TestingGerm-Line MutationHigh-Throughput Nucleotide SequencingHumansMaleMelanomaMiddle AgedNeural Networks, ComputerPredictive Value of TestsProstatic NeoplasmsSensitivity and SpecificityConceptsAmerican College of Medical Genetics and GenomicsGermline genetic testingCancer predisposition genesDetection of pathogenic variantsVariant detection performanceACMG genesNegative predictive valuePositive predictive valuePathogenic variantsGenetic testingProstate cancer cohortCriterion reference standardVariant detectionMendelian genesProstate cancerCancer cohortGermline pathogenic variantsCross-sectional studyGenetic testing methodsGermline variant detectionMelanoma cohortPathogenic germline alterationsMain OutcomesConvenience cohortClinical data collection
2017
Cumulative Intracranial Tumor Volume Augments the Prognostic Value of Diagnosis-Specific Graded Prognostic Assessment Model for Survival in Patients with Melanoma Cerebral Metastases
Hirshman BR, Wilson BR, Ali MA, Schupper AJ, Proudfoot JA, Goetsch SJ, Carter BS, Sinclair G, Bartek J, Chiang V, Fogarty G, Hong A, Chen CC. Cumulative Intracranial Tumor Volume Augments the Prognostic Value of Diagnosis-Specific Graded Prognostic Assessment Model for Survival in Patients with Melanoma Cerebral Metastases. Neurosurgery 2017, 83: 237-244. PMID: 28973506, DOI: 10.1093/neuros/nyx380.Peer-Reviewed Original ResearchConceptsCumulative intracranial tumor volumeIntracranial tumor volumeMelanoma brain metastasesBrain metastasesPrognostic valueDS-GPATumor volumeStereotactic radiosurgeryIndependent cohortKey prognostic variablesPrognostic assessment modelPrognostic assessment scaleKarnofsky performance statusNet reclassification indexCerebral metastasesPerformance statusMelanoma patientsPrognostic utilityIntracranial metastasesReclassification indexPrognostic accuracyPrognostic scalesPrognostic variablesPatientsMelanoma cohort
2016
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. The Lancet Oncology 2016, 17: 976-983. PMID: 27267608, PMCID: PMC5526047, DOI: 10.1016/s1470-2045(16)30053-5.Peer-Reviewed Original ResearchConceptsProgressive brain metastasesUntreated brain metastasesBrain metastasis responseYale Cancer CenterBrain metastasesPhase 2 trialCell lung cancerAdverse eventsMetastasis responseCancer CenterLung cancerMelanoma cohortGrade 3 colitisGrade 3 fatigueGrade 3 pneumonitisPD-1 axisAcute kidney injuryNeurological adverse eventsPD-1 inhibitorsAcceptable safety profilePD-L1 expressionSystemic immunotherapyKidney injuryPrimary endpointNSCLC cohort
2013
Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT).
Daud A, Kluger H, Edelman G, Gordon M, Schimmoller F, Weitzman A, Samuel T, Moussa A, Flaherty K, Shapiro G. Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT). Journal Of Clinical Oncology 2013, 31: 9094-9094. DOI: 10.1200/jco.2013.31.15_suppl.9094.Peer-Reviewed Original ResearchMedian overall survivalOverall survivalMetastatic uveal melanomaUveal melanomaMelanoma cohortRandomized phase 2 studyGNA11 mutationsActivity of cabozantinibGrade 3/4 AEsSafety of cabozantinibSubstantial tumor burdenObjective tumor regressionPhase 2 studyStudy days 1Long-term followupTumor mutation statusGNAQ/GNA11 mutationsUpregulation of METEligible ptsAbdominal painMeasurable diseaseMedian PFSPrior regimensTerm FollowupMedian age
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply